Mankind Pharma
Mankind Pharma, a prominent player in the Indian pharmaceutical industry, is headquartered in New Delhi, India. Founded in 1991, the company has established itself as a leader in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and consumer healthcare items. With a strong focus on quality and innovation, Mankind Pharma has achieved significant milestones, including rapid expansion across major operational regions in India and beyond. The company is renowned for its unique formulations and commitment to affordable healthcare, positioning itself as a trusted name among healthcare professionals and consumers alike. Notable achievements include a robust market presence and recognition for its contributions to the pharmaceutical sector, making Mankind Pharma a key player in enhancing health outcomes across the region.
DitchCarbon Score
How does Mankind Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mankind Pharma's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mankind Pharma's reported carbon emissions
In 2024, Mankind Pharma reported total carbon emissions of approximately 5,831,000 kg CO2e for Scope 1 and about 17,335,000 kg CO2e for Scope 2, resulting in a combined total of about 23,166,000 kg CO2e. This marks a significant reduction from 2023, where emissions were approximately 14,519,000 kg CO2e for Scope 1 and about 29,077,000 kg CO2e for Scope 2, totalling around 43,596,000 kg CO2e. In 2022, the company disclosed emissions of approximately 15,753,000 kg CO2e for Scope 1, about 28,074,000 kg CO2e for Scope 2, and 168,000 kg CO2e for Scope 3, leading to a total of around 43,995,000 kg CO2e. Mankind Pharma has not set specific reduction targets or climate pledges, and there are no emissions data cascaded from a parent or related organization. The company has disclosed emissions data for Scope 1 and Scope 2 but has not reported on Scope 3 emissions in recent years. Overall, Mankind Pharma's commitment to reducing its carbon footprint is evident through its decreasing emissions figures, although further initiatives and targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,753,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 28,074,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 168,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mankind Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
